OPUGOTAMIG
UNII ZQ8438KPJ4

Substance Identification & Data

This profile provides standardized clinical and technical data for Opugotamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) ZQ8438KPJ4.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2779564-38-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

ZQ8438KPJ4

CAS Registry Number

2779564-38-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

OPUGOTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C206958

National Cancer Institute reference terminology for clinical and research data.

INN ID

12941

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-100

Identifier assigned by the United States Adopted Names Council.

Substance Type

Opugotamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Opugotamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Opugotamig

Common Names & Synonyms

H-gamma1 heavy chain, anti-FOLR1 (1-447) [VH (Mus musculus IGHV1-37*01 (87.8%) -(IGHD) -IGHJ4*01 (93.3%) S123>T (113), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v33 CH3 S22, A24, V86 (hole) (CH1 R120>K (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), T22>S (367), L24>A (369), Y86>V (408) (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfide with L-kappa light chain, anti-FOLR1 (1'-218') [V-KAPPA (Mus musculus IGKV3-9*01 (80.8%) -IGKJ2*01 (100%), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157'), V101 (195') (112'-218')]; scFvkh-G1(h-CH2-CH3) heavy chain, anti-FOLR1 (1''-479'') [V-KAPPA (Mus musculus IGKV5-43*01 (86.3%) -IGKJ2*03 (91.7%) S120>C (101''), CDR-IMGT [6.3.10] (27''-32''.50''-52''.89''-98'')) (1''-108'')-20-mer tetrakis(tetraglycyl-seryl) linker (109''-128'') -VH (Mus musculus IGHV5-17*02 (88.8%) -(IGHD) -IGHJ3*01 (91.7%) A128>S (246''), CDR-IMGT [8.8.11] (154''-161''.179''-186''.225''-235'')) (129''-246'') -2-mer (glycyl-seryl) linker (247''-248'') -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 CH3 E12, M14, G1v37 h S5, G1v32 CH3 W22 (knob) (hinge 1-15 C5>S (253'') (249''-263''), CH2 (264''-373''), CH3 T22>W (399'') (374''-478''), CHS K2>del (479'')) (249''-479'')]; dimer (227-259'': 230-262'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Immunoglobulin (G1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], biparatopic, bivalent; H-gamma1 heavy chain, anti-FOLR1 (1-447) [VH (Mus musculus IGHV1-37*01 (87.8%) -(IGHD) -IGHJ4*01 (93.3%) S123>T (113), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v33 CH3 S22, A24, V86 (hole) (CH1 R120>K (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), T22>S (367), L24>A (369), Y86>V (408) (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfide with L-kappa light chain, anti-FOLR1 (1'-218') [VKAPPA (Mus musculus IGKV3-9*01 (80.8%) -IGKJ2*01 (100%), CDRIMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157'), V101 (195') (112'-218')]; scFvkh-G1(hCH2-CH3) heavy chain, anti-FOLR1 (1''-479'') [V-KAPPA (Mus musculus IGKV5-43*01 (86.3%) -IGKJ2*03 (91.7%) S120>C (101''), CDR-IMGT [6.3.10] (27''-32''.50''-52''.89''-98'')) (1''-108'')-20-mer tetrakis(tetraglycyl-seryl) linker (109''-128'') -VH (Mus musculus IGHV5-17*02 (88.8%) -(IGHD) -IGHJ3*01 (91.7%) A128>S (246''), CDRIMGT [8.8.11] (154''-161''.179''-186''.225''-235'')) (129''-246'') -2-mer (glycylseryl) linker (247''-248'') -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 CH3 E12, M14, G1v37 h S5, G1v32 CH3 W22 (knob) (hinge 1-15 C5>S (253'') (249''-263''), CH2 (264''-373''), CH3 T22>W (399'') (374''-478''), CHS K2>del (479'')) (249''-479'')]; dimer (227-259'': 230-262'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Immunoglobulin, anti-(human folate receptor α) (human-Mus musculus monoclonal FR1-57 single-chain Fv fragment VL-(GGGGS)4-VH)fusion protein with peptide linker (GS) fusion protein with immunoglobulin G1 [4-serine,151-tryptophan,de-232-lysine] (human γ1-chain C region C-terminal fragment), (259→227′),(262→230′)-bis(disulfide) with immunoglobulin G1 anti-(human folate receptor α) [367-serine,369-alanine,408-valine,de-448-lysine] (human-Mus musculus monoclonal Mov-19 γ1-chain) disulfide with human-Mus musculus monoclonal Mov-19 κ-chain

immunoglobulin (G1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], biparatopic, bivalent

opugotamig [INN]